800-671-4304How Treatment Works
Detox treatment is different for each individual and can be customized based on each
person's unique needs and situations. We can help you create a plan for recovery.
Buprenorphine Extends Ketamine Anti-Suicidal Effects in New Study
A Stanford Medicine clinical trial has found that low-dose buprenorphine, a cornerstone of medication-assisted treatment for opioid use disorder, may also dramatically extend the anti-suicidal effects of ketamine infusions in patients with major depressive disorder. …
Insurance Now Covers New High-Dose Naloxone for Opioid Detox
A newly approved, high-dose naloxone nasal spray has secured a spot on the formulary of a major national health plan, a development with direct relevance for anyone going through opioid detox or supporting a loved …
DEA Rule Makes Medication-Assisted Treatment More Accessible
A landmark final rule from the Drug Enforcement Administration (DEA), published June 9, 2026, formally eliminates the long-standing X-waiver requirement for medication-assisted treatment of opioid use disorder. It also extends the window for administering injectable …
Mobile Medical Detox Reaches Seattle Tiny Home Villages
For residents of Seattle’s tiny home villages, getting to a medical detox clinic has meant navigating buses, waiting lists and a system not built for people without stable housing. Starting June 15, a clinic-on-wheels will …
Detox Education
Empowering you with the knowledge to make better life changes.
A Stanford Medicine clinical trial has found that low-dose buprenorphine, a cornerstone of medication-assisted treatment for opioid use disorder, may also dramatically extend the anti-suicidal effects of ketamine infusions in patients with major depressive disorder. …
A newly approved, high-dose naloxone nasal spray has secured a spot on the formulary of a major national health plan, a development with direct relevance for anyone going through opioid detox or supporting a loved …
A landmark final rule from the Drug Enforcement Administration (DEA), published June 9, 2026, formally eliminates the long-standing X-waiver requirement for medication-assisted treatment of opioid use disorder. It also extends the window for administering injectable …